Treatments and drugsBy Mayo Clinic Staff
There's no cure for amyloidosis. But treatment can help manage signs and symptoms and limit further production of amyloid protein. Specific treatments depend on the type of amyloidosis.
For AL amyloidosis, treatment options include:
- Chemotherapy, to stop the growth of abnormal cells that produce amyloid.
- Peripheral blood stem cell transplant, in which your own stem cells are collected from your blood and stored for a short time while you have high-dose chemotherapy. The stem cells are then returned to your body via a vein. This treatment is most appropriate for people whose disease isn't advanced and whose heart isn't greatly affected.
Treatment for other types of amyloidosis
- AA amyloidosis. The underlying condition is treated with medication — for example, an anti-inflammatory medication to treat rheumatoid arthritis.
- Hereditary amyloidosis. Liver transplantation may be an option because the protein that causes this form of amyloidosis is made in the liver.
- Dialysis-related amyloidosis. Options include changing your mode of dialysis or having a kidney transplant.
To manage ongoing signs and symptoms of amyloidosis, your doctor also may recommend:
July 09, 2015
- Pain medication
- Fluid retention medication (diuretic) and a low-salt diet
- Blood-thinning medication
- Medication to control your heart rate
- Gorevic PD. An overview of amyloidsosis. http://www.uptodate.com/home. Accessed May 4, 2014.
- Ferri FF. Ferri's Clinical Advisor 2014: 5 Books in 1. Philadelphia, Pa.: Mosby Elsevier; 2014. https://www.clinicalkey.com. Accessed May 4, 2014.
- AskMayoExpert. When should light chain amyloidosis be suspected? Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2014.
- Rajkumar SV. Clinical presentation, laboratory manifestations and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis). http://www.uptodate.com/home. Accessed May 4, 2014.
- Gorevic PD. Causes and diagnosis of secondary (AA) amyloidosis and relation to rheumatic diseases. http://www.uptodate.com/home. Accessed May 4, 2014.
- Hoffman R, et al. Hematology: Basic Principles and Practice. 6th ed. Philadelphia, Pa.: Saunders Elsevier; 2013. http://www.clinicalkey.com. Accessed May 5, 2014.
- Gertz MA. Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment. American Journal of Hematology. 2013;88:417.
- Dispenzieri A, et al. What do I need to know about immunoglobulin light chain (AL) amyloidosis? Blood Reviews. 2012;26:137.
- Vrana JA, et al. Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics. Haematologica. In press. Accessed May 5, 2014.
- Warsame R, et al. Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant. European Journal of Haematology. In press. Accessed May 5, 2014.
- Dispenzieri A, et al. High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis. Heart. 2014;100:383.
- Cook AJ. Decision Support System. Mayo Clinic, Rochester, Minn. May 8, 2014.
- Gorevic PD. Genetic factors in the amyloid diseases. http://www.uptodate.com/home. Accessed June 11, 2014.